B · Normal
[Eli Lilly raised its full-year revenue guidance to a maximum of US$92 billion and adjusted its earnings per share guidance downward] On October 29, Eli Lilly raised its full-year revenue guidance for 2026 to US$91 billion to US$92 billion from the previous US$85 billion to US$87 billion, and raised its performance profit margin guidance from 49% to 50.5% to 52% to 52.5%. However, due to the impact of research and development expenses related to business expansion in the third quarter, the full-year adjusted earnings per share guidance was lowered from US$35.50 to US$36.50 to US$35 to US$36. The company confirmed acquisition-related research and development expenses of approximately US$4.2 billion in the third quarter.
Comments